Click here

FRACT — The Global Research Infrastructure for Psychedelic & Cannabis Medicine
FRACT connects psychedelic, cannabis, and natural-medicine companies with universities, clinical partners, and qualified investors through a compliant framework for research, clinical trials, and commercialisation. From protocol design and ethics coordination to capital formation, milestone governance, and IP administration, FRACT provides the infrastructure required to move serious medical research from concept to execution. Built for the next generation of regulated medicine.
Project Application
Structured for: Psychedelics • Cannabis • Natural Medicines • Functional Compounds • Clinical Research • Preventative Medicine
Supported by the wider Hollograf Group ecosystem, including: Hollograf Institute • Institute of Psychedelic Medicines • Hollograf Labs
© FRACT.co 2025
The Problem
The psychedelic and cannabinoid sectors are entering a new phase of legitimacy. Regulatory pathways are evolving. Institutional interest is growing. Clinical demand is accelerating globally.
Yet most companies still face the same structural barriers:
  • Fragmented clinical infrastructure
  • Slow ethics pathways
  • Disconnected funding channels
  • Unclear IP structures
  • Limited investor confidence
  • Cross-border regulatory complexity
  • Escalating trial costs
At the same time, the recent evolution of U.S. cannabis scheduling policy is expected to accelerate demand for cannabinoid clinical studies, product validation, and evidence-based commercialisation. Most operators are not prepared for this transition.
FRACT was built to solve that problem.
© FRACT.co 2025
What Is FRACT
A Cross-Border Research & Commercialisation Platform
FRACT is a decentralised research exchange designed to help companies structure, fund, and execute compliant research programs in psychedelic and cannabis medicine. The platform connects:
  • Biotechnology companies
  • Psychedelic medicine developers
  • Cannabis brands and formulators
  • Universities and research institutions
  • CROs and clinical sites
  • Strategic investors and family offices
Capital & Custody (USA)
Regulated Delaware fundraising structures combined with licensed custodial escrow services ensure investor protection and regulatory compliance.
R&D Control (Australia)
Comprehensive ethics governance frameworks and rigorous research oversight maintained through Australian regulatory standards.
Field Operations (Thailand)
Efficient patient recruitment protocols and professionally managed clinical site coordination within compliant Thai facilities.
IP Licensing (Canada)
Post-trial intellectual property administration and commercial licensing managed through transparent Canadian frameworks.
FRACT provides the operational layer between scientific ambition and real-world execution.
© FRACT.co 2025
What FRACT Actually Does
From Research Proposal to Commercialisation
FRACT is designed to manage the entire lifecycle of a research initiative.
For Brands
Transform products or molecular compounds into regulator-ready clinical evidence through professional research governance, transparent reporting mechanisms, and streamlined compliance pathways. We handle the complexity of multi-jurisdictional trials whilst you maintain focus on product development and commercialisation strategy.
For Researchers
Access non-dilutive funding opportunities without sacrificing equity or institutional autonomy. Benefit from clearly defined data rights, comprehensive ethics support, and transparent execution frameworks that accelerate research timelines whilst maintaining academic rigour and publication freedom.
For Investors
Participate in psychedelic and cannabis research on a per-project basis using verified milestone tracking, licensed escrow protection, and auditable documentation systems. Gain exposure to emerging therapeutic compounds with clear risk assessment and transparent capital deployment schedules.
For Regulators
Receive consistent, comprehensive documentation packages from initial proposal through final analysis. Our standardised reporting frameworks simplify regulatory review processes and ensure compliance across international jurisdictions.
FRACT acts as the infrastructure layer that aligns all stakeholders into one coordinated system.
© FRACT.co 2025
How It Works
FRACT's streamlined process transforms research concepts into commercially viable clinical evidence through transparent, milestone-based execution.
Apply
Submit your project proposal on fract.co with clearly defined endpoints, study design specifications, and preliminary budget estimates. A project application fee of US$25,000 is required. This covers preliminary project assessment, feasibility and budget review, advisory screening, protocol and commercialisation analysis, preliminary investor readiness evaluation, and jurisdictional pathway assessment.
Advisory Review
Independent scientific, regulatory, and commercial assessment through FRACT's advisory network evaluates project merit, feasibility, and compliance requirements.
Project Structuring
Research design support, protocol refinement, budget modelling, and feasibility analysis. FRACT produces comprehensive investor dossiers and governance frameworks tailored to your research objectives.
Capital Coordination
Approved projects are introduced to qualified investors, strategic partners, and co-development structures through secure, compliant channels with full disclosure documentation.
Funding & Escrow
Investors commit capital via Delaware Series vehicles; funds are held in licensed custodial escrow with transparent release conditions tied to verified milestone completion.
Ethics & Governance
Coordination with universities, ethics committees, CROs, and jurisdictional advisors. Partner institutions conduct studies under approved ethics protocols with ongoing quality oversight.
Clinical Execution
Cross-border management of recruitment, operations, milestone tracking, and reporting. All critical events receive tamper-evident digital timestamps.
IP & Commercialisation
Resulting intellectual property is licensed to project sponsors with ongoing performance reporting, transparent royalty administration, and long-term commercial strategy.
© FRACT.co 2025
Why Now
Psychedelic & Cannabis Medicine Are Entering an Institutional Era
The market is shifting rapidly from speculative wellness into evidence-based medicine. Three major transitions are happening simultaneously:
Clinical Validation
Regulators, healthcare systems, and investors increasingly require clinical evidence and measurable outcomes.
Cannabis Reclassification Momentum
Recent U.S. policy shifts surrounding cannabis scheduling are expected to increase demand for formal research pathways, product validation, and pharmaceutical-grade data.
AI & Data-Driven Healthcare
Research, diagnostics, patient tracking, and clinical analytics are becoming more integrated and measurable.
The next generation of category leaders will not simply sell products. They will own validated data, clinical outcomes, and defensible intellectual property.
© FRACT.co 2025
Who FRACT Is Built For
Designed for Serious Operators
FRACT is built for operators who are serious about clinical evidence, regulatory compliance, and long-term commercialisation.
Psychedelic Medicine Companies
Seeking clinical validation, protocol support, and institutional credibility.
Cannabis & Cannabinoid Brands
Preparing for evidence-driven regulatory and pharmaceutical markets.
Universities & Research Institutions
Looking for funding pathways and industry collaboration.
Investors & Strategic Partners
Seeking structured exposure to emerging regulated medicine sectors.
Clinics & CROs
Participating in scalable, cross-border clinical programs.
FRACT compresses the timeline to clinical credibility by providing an integrated operational framework from day one.
© FRACT.co 2025
The FRACT Model
A Multi-Jurisdictional Research Framework
FRACT operates through a specialised international structure designed to optimise governance, compliance, execution, and IP management. This structure enables serious companies to access a globally coordinated research pathway without building the infrastructure internally.
🇺🇸 United States
Capital formation, investor structures, regulated escrow, and governance frameworks.
🇦🇺 Australia
Research governance, ethics pathways, university partnerships, and clinical oversight.
🇹🇭 Thailand
Clinical operations, patient recruitment, natural-medicine infrastructure, and cost-efficient execution.
🇨🇦 Canada
Intellectual property administration, licensing, and royalty management.
This structure enables serious companies to access a globally coordinated research pathway without building the infrastructure internally.
© FRACT.co 2025
Why Companies Use FRACT
Building Clinical Infrastructure Internally Is Expensive
Most emerging companies do not have:
  • Cross-border regulatory expertise
  • University relationships
  • Ethics coordination capacity
  • Investor networks
  • Milestone governance systems
  • IP commercialisation structures
Building this independently can take years. FRACT compresses that timeline by providing an integrated operational framework from day one.
FRACT operates through a specialised international structure:
The FRACT Infrastructure
Regulated fundraising vehicles structured as Delaware Series entities, combined with licensed custodial escrow services providing investor protection and capital security under US securities regulations.
Australia
Comprehensive ethics frameworks administered through Australian institutional review boards, research oversight mechanisms, and governance documentation compliant with National Health and Medical Research Council standards.
Thailand
Clinical site operations conducted under Thai Food and Drug Administration and Department of Thai Traditional and Alternative Medicine requirements, ensuring patient safety and regulatory compliance for all trial activities.
Canada
Intellectual property holding structures and licensing administration managed through Canadian frameworks with transparent reporting mechanisms and contractual governance.

Important Legal Notice: FRACT functions as a curated platform and governance framework. All investment participation is handled through separate, compliant documentation available exclusively to qualified parties under applicable securities laws and jurisdictional requirements. We do not offer securities directly through this website.
© FRACT.co 2025
The Hollograf Ecosystem
Part of the Wider Hollograf Group
FRACT operates within the broader Hollograf ecosystem focused on psychedelic medicine, education, AI, and regulated health innovation.
Hollograf Institute
Education, practitioner training, and psychedelic medicine programs.
Institute of Psychedelic Medicines
Clinical and professional education initiatives.
Hollograf Labs
Research, analytics, formulation science, and future molecule development.
Hollograf Clinic
Virtual and physical psychedelic-assisted therapy services, delivering regulated therapeutic programs to patients globally.
Together, the ecosystem is designed to support the evolution of regulated psychedelic and cannabinoid medicine globally.
© FRACT.co 2025
Compliance & Positioning
Built for Long-Term Legitimacy
FRACT is designed around transparency, governance, and responsible research execution. The platform is structured to support:
  • Compliant clinical coordination
  • Documented milestone tracking
  • Independent oversight
  • Long-term IP administration
  • Institution-grade reporting standards
Compliant Coordination
Structured multi-jurisdictional framework leveraging each country's regulatory strengths
Milestone Governance
Auditable, tamper-evident tracking of all critical research and funding events
Independent Oversight
Advisory board review and ethics committee coordination across all projects
IP Administration
Transparent licensing frameworks and royalty management post-trial
Institution-Grade Reporting
Standardised documentation packages for regulators, investors, and partners
FRACT does not provide medical advice, securities advice, or guarantee funding outcomes.
© FRACT.co 2025
Frequently Asked Questions
Is FRACT a fund?
No. FRACT operates as a curated platform providing research governance infrastructure and compliant project funding coordination. We facilitate connections between research opportunities and qualified investors but do not pool capital or make investment decisions on behalf of participants.
Who conducts the research?
Research activities are performed by accredited universities and contract research organisations possessing appropriate ethics approvals, regulatory permissions, and institutional capabilities. FRACT provides governance oversight but does not directly conduct clinical trials or laboratory investigations.
Does FRACT guarantee project funding?
No. FRACT packages projects for investor consideration through comprehensive due diligence and professional documentation. Funding decisions remain separate and are subject to investor discretion, regulatory requirements, and risk assessment independent of FRACT's operational role.
Who owns the intellectual property?
Intellectual property ownership and licensing arrangements depend on specific project contracts negotiated between sponsors, research institutions, and investors. FRACT administers post-trial licensing transparently per contractual agreements but does not claim ownership of research outputs.
What is the application fee?
The initial application fee is US$25,000. This covers preliminary project assessment, feasibility and budget review, advisory screening, protocol and commercialisation analysis, preliminary investor readiness evaluation, and jurisdictional pathway assessment. Submission does not guarantee funding, approval, or project acceptance.
What qualifications are required for investors?
Investment participation requires accreditation status under applicable securities regulations and completion of jurisdiction-specific qualification procedures. Requirements vary by location and are detailed in separate offering documentation provided to qualified parties.
© FRACT.co 2025
Contact
Get in Touch
Whether you represent a brand with promising compounds, a university research team, a qualified investor, or a regulatory body seeking information, we welcome enquiries about FRACT's governance frameworks and project opportunities.
Headquarters
Delaware, United States of America
Global Operations
Australia • Thailand • Canada
Email
invest@fract.co
Our international team typically responds to enquiries within 48 business hours. For project submissions, please use the application portal at fract.co to ensure proper routing and documentation.
© FRACT.co 2025
Legal Disclaimer
This website is provided for informational purposes only and does not constitute an offer to sell securities, medical advice, legal advice, or investment solicitation. Participation in any research or investment opportunity is subject to separate agreements, regulatory requirements, and jurisdictional eligibility.

Important Notice: Nothing contained herein constitutes an offer to sell, solicitation of an offer to buy, or recommendation of any security or investment product. Opportunities are available exclusively to qualified parties under applicable securities laws and regulatory frameworks.
FRACT does not provide legal advice, tax guidance, or financial recommendations. Prospective participants should consult qualified independent advisors regarding suitability, risk factors, and regulatory implications relevant to their specific circumstances and jurisdictions.
Forward-looking statements regarding research outcomes, commercialisation potential, or therapeutic applications involve inherent uncertainties and should not be construed as guarantees of future results. Psychedelic and cannabis research remains subject to evolving regulatory landscapes and scientific validation processes.
All forward-looking statements are subject to risks and uncertainties. All trademarks, service marks, and trade names referenced are property of their respective owners. Unauthorised reproduction or distribution of website content is prohibited.
© FRACT.co 2025
Privacy & Data Protection
FRACT maintains rigorous data protection standards consistent with international privacy regulations including GDPR, PIPEDA, and applicable US state privacy laws. We implement comprehensive technical and organisational measures to safeguard sensitive research data, personal information, and commercial intellectual property.
Data Protection Principles
  • Purpose limitation and minimal data collection protocols
  • Encryption for data in transit and at rest
  • Role-based access controls with audit logging
  • Regular security assessments and penetration testing
  • Incident response procedures and breach notification protocols
  • Data retention policies aligned with regulatory requirements
Research participants' personal information is handled in strict accordance with ethics protocols and applicable privacy legislation. Clinical data transfers across jurisdictions comply with international data protection frameworks.
For detailed information regarding data processing activities, please review our complete Privacy Policy available at fract.co/privacy or contact our data protection officer at privacy@fract.co.
© FRACT.co 2025
Join the FRACT Network
FRACT is building the infrastructure for the next generation of psychedelic and cannabis medicine research. We invite qualified stakeholders to explore partnership opportunities and participate in advancing evidence-based therapeutic development.
Research Institutions
Universities and contract research organisations seeking non-dilutive funding, streamlined governance, and transparent project execution frameworks.
Commercial Sponsors
Brands with promising compounds requiring regulator-ready evidence, professional research governance, and compliant clinical trial execution.
Qualified Investors
Accredited investors seeking exposure to psychedelic and cannabis research opportunities with transparent milestone tracking and regulated governance structures.
Our growing network spans multiple continents and therapeutic areas, united by commitment to scientific rigour, ethical excellence, and transparent stakeholder communication.
© FRACT.co 2025
Building the Future of Psychedelic & Cannabis Research Infrastructure
Whether you are developing:
  • Psychedelic therapies
  • Cannabinoid medicines
  • Functional compounds
  • Preventative health solutions
  • Clinical research initiatives
FRACT provides the infrastructure to help serious projects move forward.
Our Vision
Creating the foundational infrastructure layer that enables psychedelic and cannabis research to scale responsibly, accelerating therapeutic development whilst maintaining unwavering commitment to scientific integrity, patient safety, and transparent communication.
Our Mission
Connecting research capability with commercial capital through compliant, transparent governance frameworks that serve brands, universities, investors, and regulators across multiple jurisdictions.
The next generation of category leaders will own validated data, clinical outcomes, and defensible intellectual property. FRACT exists to make that possible.
🌐 fract.co
📧 invest@fract.co
Part of the Hollograf Group
© FRACT.co 2025